Stifel initiated Buy coverage of Immatics stock at USD 15 target

Published on 10/15/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stifel initiated coverage with a USD 15 target on October 13, 2026. Immatics stock costs EUR 6.23 on October 15, 2026 at Lang & Schwarz.

Clinical pipeline and earnings context

Stifel initiated coverage with a Buy rating and a USD 15.00 target on October 13, 2026.
Immatics reported USD 10.44 million in quarterly revenue on August 18, 2026, below USD 12.42 million consensus.
Immatics stock trades at EUR 6.23 at 1:58 p.m. CEST at Lang & Schwarz on October 15, 2026.

IMTX, NL0015285941, Illustration mit AI erstellt.

Immatics (ISIN NL0015285941) was trading at EUR 6.23 at Lang & Schwarz on October 15, 2026, at 1:58 p.m. CEST. Stifel initiated coverage with a Buy rating and a USD 15.00 price target on October 13, 2026, as Markets Insider reported. The move gives investors a fresh valuation reference for a clinical-stage cancer company whose pipeline remains dependent on clinical execution.

What does the USD 15 target mean?

Stifel's USD 15.00 target was 113.68 percent above Immatics' USD 7.02 Nasdaq close on October 14, 2026, based on the figures published by Nasdaq. The report linked the view to Immatics' PRAME-HLA programs and its anzu-cel therapy for melanoma. That gap is a valuation signal, not a forecast of near-term earnings.

Three dated milestones shape the story

On August 18, 2026, Immatics reported quarterly revenue of USD 10.44 million against a USD 12.42 million consensus estimate, while adjusted earnings per share were a loss of USD 0.53 versus an expected loss of USD 0.47, according to MarketBeat. On August 26, 2026, Perceptive Advisors purchased 863,060 shares at an average USD 8.69, for a total value of USD 7.50 million, the same report said. On October 13, 2026, Stifel initiated its Buy rating and set the USD 15.00 target, making the analyst action the latest dated milestone.

Immatics describes its strategy as a PRAME-focused franchise spanning T-cell therapies and T-cell receptor bispecifics on its investor page. The company reported 704 full-time employees in the available company profile and is headquartered in Tuebingen, Germany, while its primary listing is Nasdaq under IMTX.

Stock stays tied to clinical execution

MarketBeat put Immatics' market capitalization at USD 956.8 million on October 15, 2026, while also reporting a new 52-week low of USD 6.73. The contrast between that valuation and Stifel's USD 15.00 target leaves clinical data, funding needs and execution as the central variables for the investment case.

Price and market value

Immatics stock was trading at EUR 6.23 at Lang & Schwarz on October 15, 2026, at 1:58 p.m. CEST. The Nasdaq-listed stock had a market capitalization of USD 956.8 million on October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Immatics stock.